Chemagis Acquires Active Ingredient Plant From Aventis in Wiesbaden
10-01-2002 - Effective October 1, Chemagis (Germany) GmbH is taking over an active ingredient plant from Aventis Pharma Deutschland GmbH in Wiesbaden. About 60 jobs affected by the sale will remain and the transfer to Chemagis ensures their long-term future.
"First and foremost, our objective was to find a future-oriented solution for our employees in Wiesbaden. Chemagis is the ideal partner in this respect. This company has made a name for itself as a manufacturer of pharmaceutical active ingredients and is looking to expand its European market position further by way of its engagement in Wiesbaden," said Dr. Rudolf Lehnert, Head of Active Ingredients at Aventis Pharma Deutschland GmbH.
Aventis and Chemagis have also reached an agreement on a long-term supply contract for the active ingredient pentoxifylline, which is produced at the plant. Chemagis will at the same time be taking over the seven percent shareholding of Aventis in Infraserv Wiesbaden, the operator of the Kalle-Albert industrial park.
Chemagis specializes in the manufacture of pharmaceutical active ingredients. With approximately 160 employees, Chemagis generates annual sales of over $40 million. Chemagis is a subsidiary of the Israeli Agis Industries (1983) Ltd. Agis is the second-largest pharmaceutical corporation in Israel. Agis has approximately 1,900 employees and generates annual sales of around $290 million.
Other news from the department business & finance
